Kai Deng

Dr. Kai Deng

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Immunity
Verified
Journal Article
Closed access
LSLiang Shan
Liang Shan
KDKai Deng
Kai Deng
NSNeeta S. Shroff
Neeta S. Shroff
CDChristine M. Durand
Christine M. Durand
SRS. Alireza. Rabi
S. Alireza. Rabi
RSRobert F. Siliciano
Robert F. Siliciano

2 August 2016 in Nature
Verified
Journal Article
Closed access
PDF file
RHRan He
Ran He
SHShiyue Hou
Shiyue Hou
CLCheng Liu
Cheng Liu
AZAnli Zhang
Anli Zhang
QBQiang Bai
Qiang Bai
LYLilin Ye
Lilin Ye

7 January 2015 in Nature
Verified
Journal Article
Open access
PDF file
KDKai Deng
Kai Deng
MPMihaela Pertea
Mihaela Pertea
ARAnthony Rongvaux
Anthony Rongvaux
LWLeyao Wang
Leyao Wang
CDChristine M. Durand
Christine M. Durand
RSRobert F. Siliciano
Robert F. Siliciano
Despite receiving antiretroviral therapy, most patients with HIV still have latent reservoirs of the virus; here, these reservoirs are shown to be dominated by viruses with cytotoxic T lymphocyte escape mutations, with potential implications for the development of therapeutic vaccines. Antiretroviral therapy does not cure HIV-1 infection: despite drug treatment, most patients still have latent reservoirs of the virus. This study of immune cells isolated from 30 HIV-1-infected patients who had been on antiretroviral therapy for at least two years and had maintained undetectable plasma HIV-1 RNA levels, shows that these viral reservoirs are dominated by viruses with cytotoxic T lymphocyte escape mutations. This finding implies that future directions in therapeutic vaccine design may need to focus on boosting broad cytotoxic T lymphocyte responses. Despite antiretroviral therapy (ART), human immunodeficiency virus (HIV)-1 persists in a stable latent reservoir1,2, primarily in resting memory CD4+ T cells3,4. This reservoir presents a major barrier to the cure of HIV-1 infection. To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed5 and tested both in vitro and in vivo6,7,8. A key remaining question is whether virus-specific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells in ART-treated patients after latency is reversed. Here we show that there is a striking all or none pattern for CTL escape mutations in HIV-1 Gag epitopes. Unless ART is started early, the vast majority (>98%) of latent viruses carry CTL escape mutations that render infected cells insensitive to CTLs directed at common epitopes. To solve this problem, we identified CTLs that could recognize epitopes from latent HIV-1 that were unmutated in every chronically infected patient tested. Upon stimulation, these CTLs eliminated target cells infected with autologous virus derived from the latent reservoir, both in vitro and in patient-derived humanized mice. The predominance of CTL-resistant viruses in the latent reservoir poses a major challenge to viral eradication. Our results demonstrate that chronically infected patients retain a broad-spectrum viral-specific CTL response and that appropriate boosting of this response may be required for the elimination of the latent reservoir.

12 September 2023 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
HJHao-Ran Jin
Hao-Ran Jin
JWJin Wang
Jin Wang
ZWZi-Jing Wang
Zi-Jing Wang
MXMing-Jia Xi
Ming-Jia Xi
BXBi-Han Xia
Bi-Han Xia
JYJinLin Yang
JinLin Yang
Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and survive in unfavorable environments that lack oxygen and nutrients, tumor cells undergo metabolic transformations to exploit various ways of acquiring lipid and increasing lipid oxidation. In addition, stromal cells and immune cells in the tumor microenvironment also undergo lipid metabolic reprogramming, which further affects tumor functional phenotypes and immune responses. Given that lipid metabolism plays a critical role in supporting cancer progression and remodeling the tumor microenvironment, targeting the lipid metabolism pathway could provide a novel approach to cancer treatment. This review seeks to: (1) clarify the overall landscape and mechanisms of lipid metabolic reprogramming in cancer, (2) summarize the lipid metabolic landscapes within stromal cells and immune cells in the tumor microenvironment, and clarify their roles in tumor progression, and (3) summarize potential therapeutic targets for lipid metabolism, and highlight the potential for combining such approaches with other anti-tumor therapies to provide new therapeutic opportunities for cancer patients.

26 September 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
LXLei Xu
Lei Xu
JWJun Wang
Jun Wang
YLYulin Liu
Yulin Liu
LXLiangfu Xie
Liangfu Xie
BSBin Su
Bin Su
HCHu Chen
Hu Chen
The safety of CRISPR (clustered regularly interspaced short palindromic repeats)–based genome editing in the context of human gene therapy is largely unknown. CCR5 is a reasonable but not absolutely protective target for a cure of human immunodeficiency virus type 1 (HIV-1) infection, because CCR5-null blood cells are largely resistant to HIV-1 entry. We transplanted CRISPR-edited CCR5-ablated hematopoietic stem and progenitor cells (HSPCs) into a patient with HIV-1 infection and acute lymphoblastic leukemia. The acute lymphoblastic leukemia was in complete remission with full donor chimerism, and donor cells carrying the ablated CCR5 persisted for more than 19 months without gene editing–related adverse events. The percentage of CD4+ cells with CCR5 ablation increased by a small degree during a period of antiretroviral-therapy interruption. Although we achieved successful transplantation and long-term engraftment of CRISPR-edited HSPCs, the percentage of CCR5 disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.)

20 April 2020 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
XCXiangyu Chen
Xiangyu Chen
RLRen Li
Ren Li
ZPZhiwei Pan
Zhiwei Pan
CQChunfang Qian
Chunfang Qian
YYYang Yang
Yang Yang
LYLilin Ye
Lilin Ye